Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Earnings Preview: What to Expect From Pfizer’s Report

April 14, 2026 at 11:08 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

With a market cap of $155.5 billion, Pfizer Inc. (PFE) is one of the world’s largest biopharmaceutical companies, focused on discovering, developing, manufacturing, and commercializing medicines and vaccines. Headquartered in New York, Pfizer operates globally and plays a central role in addressing major health conditions across oncology, vaccines, immunology, cardiovascular, and rare diseases.

The pharmaceutical giant is expected to announce its fiscal first-quarter earnings for 2026 before the market opens on Sunday, May 5. Ahead of the event, analysts expect PFE to report a profit of $0.74 per share on a diluted basis, down 19.6% from $0.92 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

For the current year, analysts expect PFE to report EPS of $2.98, down 7.5% from $3.22 in the prior year. Moreover, its EPS is expected to decline 5.4% year over year to $2.82 in fiscal 2027.

PFE stock has surged 24.8% over the past year, underperforming the S&P 500 Index’s ($SPX) 28.4% gains. However, it surpassed the State Street Health Care Select Sector SPDR Fund’s (XLV) 8.1% returns over the same time frame.

On Mar. 23, Pfizer and Valneva SE reported Phase 3 results for their Lyme disease vaccine candidate showing efficacy of around 73–75% in reducing confirmed cases after the fourth dose. While the primary endpoint was not fully met due to fewer-than-expected cases in the trial, the vaccine demonstrated clinically meaningful protection, and the companies plan to move forward with regulatory submissions, expressing confidence in its potential. Its shares rose marginally in the next trading session.

Analysts’ consensus opinion on PFE stock is cautious, with a “Hold” rating overall. Out of 28 analysts covering the stock, eight advise a “Strong Buy” rating, one suggests a “Moderate Buy,” 16 give a “Hold,” and three recommend a “Strong Sell.” PFE’s average analyst price target is $29.13, indicating a potential upside of 6.5% from the current price levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article